| Title: | Unveiling the outcomes and developing targeted therapies in chronic liver disease |
| Lead Institution: | University of California, San Diego |
| Principal investigator: |
Application 930515
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
About
Chronic liver disease (CLD) is a heterogenous condition with various etiologies including metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-associated liver disease (MetALD), and alcohol-associated liver disease (ALD), and primary sclerosing cholangitis (PSC) with concomitant ulcerative colitis (UC). These subtypes exhibit distinct clinical trajectories and require individualized management; however, differences in outcomes and underlying risk factors remain unclear in large populations. This project aims to address this gap using the UK Biobank, a large-scale, population-based dataset integrating demographics, lifestyle, imaging, laboratory data, proteomics, metabolomics, and genomics. !We will evaluate major CLD outcomes such as mortality, hepatic decompensation, hepatocellular carcinoma, and extrahepatic complications across etiological subtypes. Through an unbiased, data-driven approach, we aim to identify high-impact risk factors and stratify patients by risk profiles, enabling the development of precision management strategies. Our group has previously examined alcohol use, gut-liver axis dysfunction, and phage therapy in CLD progression; however, these studies were limited by small, homogeneous cohorts. By leveraging the diversity and scale of the UK Biobank, we will overcome these limitations and identify generalizable determinants of adverse outcomes. !The scientific rationale lies in bridging discovery and translation. Risk factors identified in population-level analyses will inform targeted interventions, while preclinical studies will validate causality and therapeutic potential. This integrative strategy linking epidemiology, omics, and mechanistic research will advance our understanding of CLD and guide the development of tailored therapies to improve outcomes.1 Publication
| Pub ID | Title | Author(s) | Year | Journal |
|---|---|---|---|---|
| 20086 | Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis | Takao Miwa (+7) | 2026 | Alimentary Pharmacology & Therapeutics |
Enabling scientific discoveries that improve human health